Bicycles® can be developed to modulate single targets as stand-alone therapeutics (Bicycles), bind two targets where two Bicycles are coupled together (bispecific Bicycles), or deliver other molecular cargos (Bicycle Drug Conjugates® or BDCs, Bicycle Therapeutics’ initial focus). These cargos can include toxins, immune modulators, small molecules, biologics, radio-labelled ligands or nucleic acids.
One advantage of identifying Bicycles attached to a large phage particle, is that this “molecular bulk” can be removed and replaced without changing the binding affinity of the Bicycle. Some of these applications of the Bicycle technology are illustrated below.
BICYCLES® CAN BE USED AS SIMPLE UNELABORATED STRUCTURES AS A NEW CLASS OF THERAPEUTICS
BICYCLES® CAN ALSO BE USED TO GENERATE MORE COMPLEX MOLECULES
BICYCLES® CAN BE USED IN COMBINATION, OR WITH OTHER MOLECULAR CARGOES, TO DELIVER ADDITIONAL FUNCTIONALITY
Bicycle Therapeutics’ initial focus is on BDCs that selectively deliver payloads to tumours. The company is looking to explore its technology outside of oncology through partnerships, as exemplified by its existing collaborations with AstraZeneca in respiratory, cardiovascular and metabolic diseases and with ThromboGenics in ophthalmology.